TransMedics (TMDX) Cash from Operations Growth (3y) (2021 - 2026)
TransMedics (TMDX) Cash from Operations Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -48.14% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 50.11% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 0.50% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -14.75% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | TransMedics | 2.45 Bn | 1.98 Bn | 101.16 Mn | 69.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.07% |
| Dec 31, 2025 | 119.35% |
| Sep 30, 2025 | 90.11% |
| Jun 30, 2025 | 129.41% |
| Mar 31, 2025 | 46.27% |
| Dec 31, 2024 | 70.51% |
| Sep 30, 2024 | 39.82% |
| Jun 30, 2024 | 88.01% |
| Mar 31, 2024 | 22.33% |
| Dec 31, 2023 | 46.80% |
| Sep 30, 2023 | -2.32% |
| Jun 30, 2023 | 12.08% |
| Mar 31, 2023 | -1.94% |
| Dec 31, 2022 | 17.80% |
| Sep 30, 2022 | -36.65% |
| Jun 30, 2022 | 9.23% |
| Mar 31, 2022 | -36.32% |
| Dec 31, 2021 | -2.80% |
| Sep 30, 2021 | -15.53% |
| Jun 30, 2021 | 9.50% |